Breaks Categories: News

ThursdayFeb 10, 2022 12:12 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Receives Notice of Allowance by USPTO for Smart Medical Inhaler System

RYAH Group (CSE: RYAH) today announced that the U.S. Patent and Trademark Office (the “USPTO”) has issued a Notice of Allowance for U.S. patent application number 15/924,172, filed in respect of the company's IoT-powered, Smart Medical Inhaler system by its wholly owned subsidiary, Potbotics Inc. The hybrid conduction and convection RYAH Smart Medical Inhaler was recently granted Medical Device Certification under ISO 13485:2016/MDSAP and EN ISO 13485:2016 standards for both its hardware and software. “Receiving this Notice of Allowance by the USPTO on our Smart Medical Inhaler is the result of dedication and great effort by all of our product…

Continue Reading

ThursdayFeb 10, 2022 12:03 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release Q2 Financial Report, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced that it will report its second-quarter financial results next week on Feb. 15, 2022; the results will cover the period ending Dec. 31, 2021. The company has scheduled a conference call and webcast to discuss the report; the call will be held Feb. 15, 2021, at 2 p.m. ET. Those interested can dial +1 (855) 605-1745 (United States and Canada) or +1 (914) 987-7959 (international) using conference ID 8645175. In addition, the company’s full financial statements and related MD&A along with a replay of the…

Continue Reading

TuesdayFeb 08, 2022 1:37 pm

BioMedNewsBreaks – Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Exclusive Dealer Identified as Supplier for Health Canada’s Special Access Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company aiming to transform the treatment of mental health and addiction disorders. The company today announced that Health Canada has included the dealer’s license Mydecine operates under as a supplier for the Special Access Program (“SAP”), which allows health care providers to request specific drugs for approved patients who have not responded to other treatment options. Available to Mydecine through its exclusive agreement with Applied Pharmaceutical Innovation (“API”), the licensed dealer facility contains a unique research and development infrastructure as well as a manufacturing facility in Edmonton, Canada. With the…

Continue Reading

ThursdayFeb 03, 2022 11:30 am

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Strengthens Board with Appointment of Dr. Victoria Hale

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s board of directors. A pharmaceutical scientist, executive and global health social entrepreneur, Dr. Hale currently serves as chair of the board of the Multidisciplinary Association for Psychedelic Studies (“MAPS”). A non-profit research and educational organization, MAPS works to raise awareness of psychedelics and help scientists design, fund and obtain regulatory approval of studies measuring the safety and effectiveness of psychedelics for therapeutic use. “We are thrilled to welcome…

Continue Reading

TuesdayFeb 01, 2022 12:12 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) at the Forefront of Research Investigating Psilocybin Compound for Smoking Cessation

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Mydecine has announced that, in preparation for its FDA pre-Investigational New Drug (“IND”) meeting on Feb. 28, the company has submitted a pre-IND briefing package to the U.S. Food and Drug Administration (“FDA”) for a clinical study evaluating MYCO-001 in a structured smoking cessation treatment program. Principal Investigator Dr. Matthew Johnson, Ph.D., professor of psychiatry and behavioral sciences at Johns Hopkins University, will lead the study that will assess the safety and efficacy of psilocybin-assisted…

Continue Reading

MondayJan 31, 2022 1:50 pm

BioMedNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) Partners with Renowned Expert to Discuss Alcohol Use Disorder and Trauma at Upcoming Virtual Event

Clearmind Medicine (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) is a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems. The company has announced that, as part of its “Psychedelics for Alcoholism” events series, it will host Dr. Gabor Maté to discuss alcohol use disorder and how Clearmind’s candidate treatment may create a clear path to dealing with trauma. The special virtual event, slated to take place starting at 12 p.m. ET on Feb. 3, 2022, is open and free to all, with registration required. Renowned speaker and bestselling author Dr.…

Continue Reading

ThursdayJan 27, 2022 10:28 am

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Announces MOU with Bazelet Pharma Ltd., Closing of Initial Tranche of Private Placement

RYAH Group (CSE: RYAH) today announced its entry into a memorandum of understanding (“MOU”) with Bazelet Pharma Ltd. and affiliates (together, “Bazelet”), the largest medical cannabis processing company in Israel, serving thousands of patients. According to the update, the collaboration is aimed at servicing Bazelet's patients using RYAH Smart Inhalers and data analytics, once certified as a medical device in Israel, with the goal of providing safe and accurate patient inhalation therapies in plant medicine. “Bazelet brings extraordinary depth and expertise within a well-established and fast-growing medical cannabis market. We're excited to be collaborating with Bazelet in bringing our smart…

Continue Reading

TuesdayJan 25, 2022 11:25 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Ranked No. 1 Globally in Multi-Cancer Screening and Detection Test Volume

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that Frost & Sullivan Company, a leading and well-known U.S. market analysis and research firm, has ranked AnPac Bio globally as number one in worldwide multiple cancer screening and detection volume in a recent research report. Based on data accumulated through the end of 2020, the report included next generation cancer screening and detection technologies, including circulating tumor cells (“CTCs”), circulating-DNA (“CT-DNA”), exosome, cancer differentiation analysis (“CDA”), mRNA, and other emerging technologies. Specifically, for next generation cancer screening and detection, the report ranked…

Continue Reading

MondayJan 24, 2022 12:37 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Partnership to Treat PTSD in Veterans

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced a partnership with Combat Stress and the King's College London to utilize psilocybin as part of a psychoactive-assisted psychotherapy treatment for post-traumatic stress disorder (“PTSD”) in veterans. According to the update, Combat Stress, the leading charity aiding veterans’ mental health in the United Kingdom, will be one of several sites for Mydecine’s upcoming clinical trials. “The team is thrilled to be conducting studies within the veteran population where the help is needed most,” said…

Continue Reading

ThursdayJan 20, 2022 12:12 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor 2022 Top Picks Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate in the Virtual Investor 2022 Top Picks Conference at 11:00 a.m. ET on Wednesday, Jan. 26, 2022. As part of the virtual event, the company will provide a corporate presentation followed by an interactive Q&A session. In addition to the moderated portion, investors and attendees will have the opportunity to submit questions live during the event or in advance of the conference via www.VirtualInvestorCo.com.…

Continue Reading